Desvenlafaxine Succinate Tablet, Film Coated, Extended Release
Product Images NDC 50090-7468

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine Succinate (NDC 50090-7468). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (E104f9c6 757f 4126 9479 8d50db02fe66 01)

Chemical structure diagram of Desvenlafaxine Succinate, an extended-release oral tablet active ingredient. The image shows the molecular configuration featuring aromatic and cyclohexane rings with hydroxyl and carboxylic acid groups.*

FDA Label Image

Image (E104f9c6 757f 4126 9479 8d50db02fe66 02)

A forest plot graph titled 'Impact of Intrinsic Factors (Renal, Hepatic Impairment and Population Description) on Desvenlafaxine Pharmacokinetics.' It displays geometric mean ratios with 90% confidence intervals for Cmax and AUC across different categories of renal impairment, hepatic impairment, gender, and age groups relative to a reference. The x-axis represents change relative to reference, ranging from 0.5 to 3.5.*

FDA Label Image

Image (E104f9c6 757f 4126 9479 8d50db02fe66 03)

A pharmacokinetic chart showing the effect of CYP3A4 inhibitor ketoconazole on Desvenlafaxine pharmacokinetics. It presents the geometric mean ratio and 90% confidence intervals for Cmax and AUC, with values indicating changes relative to reference ranging from approximately 1.0 to 1.5.*

FDA Label Image

Image (E104f9c6 757f 4126 9479 8d50db02fe66 04)

A figure illustrating the effects of desvenlafaxine at various doses on the pharmacokinetics of other drugs, categorized by CYP2D6, CYP3A4, and combined CYP2D6 & CYP3A4 substrates. The chart shows geometric mean ratios with 90% confidence intervals for pharmacokinetic parameters like Cmax and AUC relative to reference values for drugs including Desipramine, Midazolam, Tamoxifen, and Aripiprazole.*

FDA Label Image

Image (E104f9c6 757f 4126 9479 8d50db02fe66 05)

A line graph titled 'Estimated Proportion of Relapses vs. Number of Days since Randomization (Study 5)' showing relapse rates over time. The x-axis represents time to relapse in days from randomization (0 to 200 days), and the y-axis shows the estimated proportion of patients with relapse as a percentage (0 to 50%). Two lines compare Desvenlafaxine extended-release tablets 50 mg and placebo, with the placebo line showing higher relapse proportions over time.*

FDA Label Image

Image (E104f9c6 757f 4126 9479 8d50db02fe66 06)

A Kaplan-Meier curve graph showing the estimated proportion of patients with relapse (%) over time in days from randomization. Two lines compare Desvenlafaxine extended-release tablets and placebo, illustrating different relapse rates during the study period of up to about 180 days.*

FDA Label Image

Label Image (Lbl500907468)

Desvenlafaxine Succinate 25 mg extended-release film-coated tablets label by A-S Medication Solutions. The label includes dosage information, storage instructions to store at 68 to 77 degrees Fahrenheit, and a package size of 30 tablets. The product NDC is 50090-7468-0.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.